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CytokinesAstrocytes are responsible for modulating neurotransmitter systems and synaptic information process-
ing, ionic homeostasis, energy metabolism, maintenance of the blood–brain barrier, and antioxidant
and inﬂammatory responses. Our group recently published a culture model of cortical astrocytes
obtained from adult Wistar rats. In this study, we established an in vitromodel for hippocampal astrocyte
cultures from adult (90 days old) and aged (180 days old) Wistar rats. Resveratrol, a polyphenol found in
grapes and red wine, exhibits antioxidant, anti-inﬂammatory, anti-aging and neuroprotective effects that
modulate glial functions. Here, we evaluated the effects of resveratrol on GSH content, GS activity, TNF-a
and IL-1b levels in hippocampal astrocytes from newborn, adult and aged Wistar rats. We observed a
decrease in antioxidant defenses and an increase in the inﬂammatory response in hippocampal astrocytes
from adult and aged rats compared to classical astrocyte cultures from newborn rats. Resveratrol
prevented these effects. These ﬁndings reinforce the neuroprotective effects of resveratrol, which are
mainly associated with antioxidant and anti-inﬂammatory activities.
 2014 Elsevier Ltd. All rights reserved.1. Introduction
Astrocytes are the more versatile cells in the central nervous
system (CNS) that serve a wide range of adaptive functions
(Belanger et al., 2011; Maragakis and Rothstein, 2006). These cells
are responsible for modulating neurotransmitter systems and syn-
aptic information processing, ionic homeostasis, energy metabo-
lism, maintenance of the blood–brain barrier, and antioxidant
and inﬂammatory responses (Maragakis and Rothstein, 2006;
Nedergaard et al., 2003; Parpura et al., 2012; Ransom and Ransom,
2012; Wang and Bordey, 2008). Astrocytes take up glutamate
through their high afﬁnity glutamate transporters, and convert it
into glutamine via glutamine synthetase (GS – EC 6.3.1.2) (Ander-
son and Swanson, 2000; Banerjee et al., 2008; Danbolt, 2001; Hertz
and Zielke, 2004). Glutamate is also a substrate for glutathione
(GSH), a major antioxidant molecule in the brain (Dringen, 2000;
Hertz and Zielke, 2004). Furthermore, astrocytes synthesize andrelease the main proinﬂammatory cytokines, including tumor
necrosis factor-a (TNF-a) and interleukin-1b (IL-1b) (Santello and
Volterra, 2012; Tuttolomondo et al., 2008).
Studies using primary cultures of astrocytes have made essen-
tial contributions to the understanding of astrocytic functions
and neuronal-astrocytic interactions (Hertz et al., 1998; Lange
et al., 2012; Skytt et al., 2010). These cultures have been an invalu-
able tool for studying the roles of astrocytes in physiological and
pathological conditions (Lange et al., 2012). Our group recently
developed a protocol for the routine preparation of cortical astro-
cyte cultures obtained from adult (90 days old) Wistar rats (Souza
et al., 2013). Adult astrocytes contain well established synaptic
connections compared to newborn tissues (Diamond et al., 1975;
Souza et al., 2013; Sun et al., 2013); thus, this culture model can
better contribute to understanding the cellular, biochemical,
molecular and physiological properties of the adult brain.
Resveratrol (3,5,40-trihydroxy-trans-stilbene) is a phytoalexin
found in grapes, peanuts and wine (predominately red wine); it
exhibits antioxidant, anti-inﬂammatory, anti-aging, cardioprotec-
tive and antitumor activities (Baur and Sinclair, 2006; Bobermin
et al., 2012; Delmas et al., 2005; Jang et al., 1997; Quincozes-Santos
et al., 2013). Resveratrol also protects neurons and astrocytes in
several neurological disease models, such as epilepsy and stroke
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Khan et al., 2010; Sakata et al., 2010; Wu et al., 2009). Our group
has shown that resveratrol modulates important glial functions,
including glutamate uptake, GS activity, GSH levels and inﬂamma-
tory response (Bobermin et al., 2012; de Almeida et al., 2007;
dos Santos et al., 2006; Quincozes-Santos et al., 2013, 2009;
Quincozes-Santos and Gottfried, 2011; Souza et al., 2013). Although
the protective role of resveratrol in the CNS is well established, the
mechanisms of these effects are not fully understood.
The aim of this study was to evaluate the effects of resveratrol
on antioxidant defenses and the inﬂammatory response in hippo-
campal astrocytes from newborn, adult and aged Wistar rats. In
addition to classical astrocyte cultures from newborn rats, we
established an in vitromodel using hippocampal astrocyte cultures
from adult (90 days old) and aged (180 days old) Wistar rats. We
treated hippocampal astrocyte cultures with resveratrol and mea-
sured GSH levels, GS activity and TNF-a and IL-1b levels. We also
evaluated the age-related effects of resveratrol.
2. Materials and methods
2.1. Materials
Dulbecco’sModiﬁed Eagle’sMedium/F12 (DMEM/F12) and other
materials for cell cultures were purchased from Gibco. DNase,
o-phtaldyaldehyde, c-glutamylhydroxamate and anti-b-tubulin III
were purchased from Sigma–Aldrich. ELISA for TNF-a and IL-1b
were purchased from PeproTech. Polyclonal anti-GFAP was pur-
chased from Dako. Monoclonal anti-NeuNwas purchased fromMil-
lipore and anti-CD11b/c was purchased from Invitrogen. All other
chemicals were obtained from common commercial suppliers.
2.2. Animals
Male Wistar rats (1, 90 and 180 days old) were obtained from
our breeding colony (Department of Biochemistry, UFRGS, Brazil)
and maintained in a controlled environment (12 h light/12 h dark
cycle; 22 ± 1 C; ad libitum access to food and water). All animal
experiments were performed in accordance with the NIH Guide
for the Care and Use of Laboratory Animals and were approved
by the Federal University of Rio Grande do Sul’s Animal Care and
Use Committee (process number 21215).
2.3. Cell cultures
2.3.1. Primary astrocyte cultures
Male Wistar rats (1, 90 and 180 days old) had their hippocampi
aseptically removed from cerebral hemispheres. All meninges were
removed. During the dissection, the hippocampi were kept in HBSS
(Hank’s Balanced Salt Solution) containing 0.05% trypsin and
0.003% DNase at 37 C for 8 min. The tissue was then mechanically
dissociated for 7 min using a Pasteur pipette and centrifuged at
100g for 5 min. The cells were resuspended in HBSS containing
DNase (0.003%) and left for decantation for 20 min. The superna-
tant was collected and centrifuged for 7 min (400g). The cells from
the supernatant were resuspended in DMEM/F12 [10% fetal bovine
serum (FBS), 15 mM HEPES, 14.3 mM NaHCO3, 1% fungizone and
0.04% gentamicin] and plated in 6- or 24-well plates pre-coated
with poly-L-lysine at a density of 3–5  105 cells/cm2. The cells
were cultured at 37 C in a 95% air/5% CO2 incubator.
2.3.2. Cell culture maintenance
The ﬁrst medium exchange occurred 24 h after obtaining a
culture. The culture maintenance has been described elsewhere
(Souza et al., 2013). For hippocampal astrocytes from 90 to
180 days old, the medium change occurred once every two daysduring the 1st week and once every four days beginning in the
2nd week. Starting in the 3rd week, the cells received a medium
supplemented with 20% FBS and around the 4th to 5th week the
cells reached the conﬂuence. However, in the cultures obtained
from newborn rats, the cells reached the conﬂuence around 2nd
week. Once the cells reached conﬂuence, they were used for the
experiments. Fig. 1A, B and C shows the immunocytochemistry
for GFAP (glial ﬁbrillary acidic protein) in newborn, adult and aged
astrocytes with an intense cytoplasmic immunolabeling (95%
GFAP-positive cells after the conﬂuence for all ages), indicating
the astrocytic phenotype. To determine whether the culture con-
tained microglia or neurons after reaching conﬂuence, we used
three speciﬁc antibodies: (i) anti-CD11b/c (an antibody that recog-
nizes a speciﬁc microglial protein); (ii) anti-b-tubulin III (an anti-
body that recognizes a type of microtubule expressed exclusively
in neurons) and (iii) anti-NeuN (an antibody that recognizes a neu-
ronal protein present in neuronal nuclei). Approximately less than
5% of the cultured cells were stained positively for the microglial
marker, while neither b-tubulin III nor NeuN were detected (data
not shown). Both data are in accordance with Souza et al., 2013.
2.4. Resveratrol treatment
After cells reached conﬂuence, the culture medium was
removed and the cells were incubated in the absence or presence
of resveratrol (10 lM) for 24 h at 37 C in a 95% air/5% CO2 incuba-
tor in DMEM/F12 with 1% FBS. Ethanol 0.25% was used as vehicle
for resveratrol; in all parameters analyzed, the results obtained
with ethanol were not different from those obtained in the basal
conditions without ethanol.
2.5. Immunocytochemistry
Immunocytochemistry was performed as described previously
by our group (Souza et al., 2013). Brieﬂy, cell cultures were ﬁxed
with 4% paraformaldehyde for 20 min and permeabilized with
0.1% Triton X-100 in PBS for 5 min at room temperature. After
blocking overnight with 4% albumin, the cells were incubated over-
night with anti-GFAP (1:400), anti-CD11 (1:400), anti-b-tubulin III
(1:500) and anti-NeuN (1:50) at 4 C; this was followed by PBS
washes and incubation with a speciﬁc secondary antibody conju-
gated with Alexa Fluor 488 (green staining) for 1 h at room tem-
perature. For all immunostaining-negative controls, the reactions
were performed by omitting the primary antibody. No reactivity
was observed when the primary antibody was excluded. Cell nuclei
were stained with 0.2 lg/ml of 40,60-diamidino-2-phenylindole
(DAPI). The cells were visualized with a Nikon inverted microscope
and the images were transferred to a computer with a digital cam-
era (Sound Vision Inc.).
2.6. Glutathione content
GSH levels were assessed as previously described (Souza et al.,
2013). Astrocyte homogenates (50 mg) were diluted in 100 mM so-
dium phosphate buffer (pH 8.0) containing 5 mM EDTA, and the
protein was precipitated with 1.7% meta-phosphoric acid. The
supernatant was assayed with o-phthaldialdehyde (1 mg/ml meth-
anol) at room temperature for 15 min. Fluorescence was measured
using excitation and emission wavelengths of 350 and 420 nm,
respectively. A calibration curve was performed with standard
GSH solutions (0–500 mM). GSH concentrations were calculated
as nmol/mg protein.
2.7. Glutamine synthetase activity
The enzymatic assaywas performed as previously described (dos
Santos et al., 2006). Brieﬂy, cell homogenate (0.1 ml – approximately
Fig. 1. Hippocampal astrocytes present GFAP. Representative images of astrocytes from (A) newborn – NB, (B) adult – AD and (C) aged – AG Wistar rats show intense
cytoplasmic immunolabeling for GFAP (95% GFAP-positive cells). Immunocytochemistry was performed as described in Section 2. All images are representative ﬁelds from
three independent experiments. Scale bar = 50 lm.
Fig. 2. Resveratrol increased GSH levels. After reached the conﬂuence, the cells
were treated in the presence or absence of 10 lM resveratrol for 24 h in DMEM/F12
with 1% FBS. GSH levels were measured as described in Section 2. Data represent
the mean ± S.E.M of three independent experimental determinations performed in
triplicate and analyzed statistically by ANOVA followed by Tukey’s test.  Indicates
signiﬁcant differences from the control,  for P < 0.01. Astrocytes were obtained
from newborn – NB, adult – AD, and aged – AG rats.
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(in mM): 10 MgCl2, 50 L-glutamate, 100 imidazole–HCl buffer (pH
7.4), 10 2-mercaptoethanol, 50 hydroxylamine–HCl and 10 ATP,
and incubated for 15 min (37 C). The reaction was stopped by the
addition of 0.4 ml of a solution containing (in mM): 370 ferric
chloride, 670 HCl, and 200 trichloroacetic acid. After centrifugation,
the absorbance of the supernatant was measured at 530 nm and
compared to the absorbance generated using standard quantities
of c-glutamylhydroxamate treated with a ferric chloride reagent.
2.8. TNF-a measurement
The TNF-a assay was carried out in an extracellular medium,
using a rat TNF-a ELISA from Peprotech (USA). The results are
expressed as the percentage of the control levels.
2.9. IL-1b measurement
IL-1b was carried out in an extracellular medium, using a rat
IL-1b ELISA from eBioscience (USA). The results are expressed as
the percentage of the control levels.
2.10. Protein determination
Protein content was measured using Lowry’s method with
bovine serum albumin as a standard (Lowry et al., 1951).
2.11. Statistical analyses
Data were analyzed statistically by one-way analysis of
variance (ANOVA), followed by Tukey’s test. P-values < 0.05 were
considered signiﬁcant. All analyses were performed using the
Statistical Package for Social Sciences (SPSS) software version 16.0.Fig. 3. Resveratrol increased GS activity. After reached the conﬂuence, the cells
were treated in the presence or absence of 10 lM resveratrol for 24 h in DMEM/F12
with 1% FBS. GS activity was measured as described in Section 2. Data represent the
mean ± S.E.M of three independent experimental determinations performed in
triplicate and analyzed statistically by ANOVA followed by Tukey’s test.  Indicates
signiﬁcant differences from the control,  for P < 0.01. Astrocytes were obtained
from newborn – NB, adult – AD, and aged – AG rats.3. Results
The GSH content decreased with age in hippocampal astrocytes
(Fig. 2). The basal values of GSH levels for astrocytes from newborn
(NB), adult (AD) and aged (AG) Wistar rats were: 30.0 ± 2.0 nmol/
mg protein (P < 0.01), 22.0 ± 2.4 nmol/mg protein (P < 0.01), and
17.0 ± 1.5 nmol/mg protein (P < 0.01), respectively. Resveratrol in-
creased GSH levels in all ages: 15% in NB astrocytes, 20% in AD
astrocytes and 30% in AG astrocytes (P < 0.01).
GS is an important marker expressed by astrocytes. In addition
to GSH content, GS activity decreased with age in hippocampal pri-
mary astrocytes and resveratrol increased GS activity (Fig. 3). The
values of GS activity were: (I) NB astrocytes: control
2.6 ± 0.2 lmol/mg protein/min, resveratrol 3.1 ± 0.3 lmol/mg
protein/min; and (II) AD astrocytes: control 2.0 ± 0.2 lmol/mg pro-
tein/min, resveratrol 2.6 ± 0.2 lmol/mg protein/min; and III) AGastrocytes: control 1.5 ± 0.1 lmol/mg protein/min, resveratrol
1.9 ± 0.2 lmol/mg protein/min, (P < 0.01 for all conditions).
As expected, in contrast to GSH levels and GS activity, the levels
of proinﬂammatory cytokines increased with age (Fig. 4). In NB
astrocytes, the basal value of TNF-a levels was 125 ± 8 pg/ml
(Fig. 4A). An increase of 20% in the basal value of TNF-a levels
was observed in AD and AG astrocytes (150 ± 10 pg/ml). Following
Fig. 4. Resveratrol decreased proinﬂammatory cytokines. After reached the con-
ﬂuence, the cells were treated in the presence or absence of 10 lM resveratrol for
24 h in DMEM/F12 with 1% FBS. TNF-a (A) and IL-1b (B) levels were measured as
described in Section 2. Data represent the mean ± S.E.M of four independent
experimental determinations performed in quadruplicate and analyzed statistically
by ANOVA followed by Tukey’s test.  Indicates signiﬁcant differences from the
control,  for P < 0.01. Astrocytes were obtained from newborn – NB, adult – AD,
and aged – AG rats.
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ages, including NB, AD and AG astrocytes, by 106 ± 8 pg/ml,
120 ± 10 pg/ml, and 115 ± 9 pg/ml, respectively (P < 0.01). The lev-
els of IL-1b presented the same proﬁle as TNF-a. For NB, AD and AG
astrocytes, the following values were observed: 90 ± 6 pg/ml,
102 ± 7 pg/ml, and 107 ± 9 pg/ml, respectively, Fig. 4B, P < 0.01.
The resveratrol treatment reduced the basal levels of IL-1b by
approximately 20% in all ages (P < 0.01).4. Discussion
The effects of resveratrol in the CNS have been studied in a vari-
ety of pathological events, including brain diseases associated with
aging, such as Alzheimer’s and Parkinson’s diseases (Huang et al.,
2011; Quincozes-Santos and Gottfried, 2011; Richard et al., 2011;
Vingtdeux et al., 2008). However, the cellular mechanisms under-
lying resveratrol-induced neuroprotection needs to be better eluci-
dated. Here, we demonstrated that resveratrol increased
antioxidant defenses and decreased proinﬂammatory cytokines
in hippocampal astrocyte cultures from newborn, adult and aged
Wistar rats.
Recently, we established and characterized a model for cultured
cortical astrocytes from adult Wistar rats (Souza et al., 2013). We
also demonstrated that these astrocytes respond to oxidative and
inﬂammatory external stimuli and resveratrol was able to protect
them against H2O2 exposure (Souza et al., 2013). Here, a culture
model of hippocampal astrocytes from adult and aged rats (90
and 180 days old, respectively) was established; we also compared
our data with a classical astrocyte culture from newborn rats.
Hippocampal astrocyte cultures from all ages presented GFAP(Fig. 1), a major cytoskeletal protein present in astrocytes, and
important glial properties, such as GS activity and GSH.
In vivo and in vitro studies have reported an age-dependent
decrease in GSH content, indicating an increasing vulnerability to
oxidative stress (Pertusa et al., 2007; Segovia et al., 2001a,b). The
vulnerability appears to be intensiﬁed in neurodegenerative dis-
eases. Moreover, aging is associated with an increase in oxida-
tive–nitrosative stress, which can lead to lipid, protein and DNA
oxidation, thereby causing cellular damage (Halliwell, 2001,
2006). GSH depletion in glial cells can induce neurotoxicity with
a consequent impairment of the glutamatergic system and in-
creased oxidative stress, which have been described in many neu-
rodegenerative diseases (Lee et al., 2010; Trotti et al., 1998;
Volterra et al., 1994a,b). GS activity also decreases with aging
and oxidative stress (Halliwell, 2006; Lewis et al., 2012; Volterra
et al., 1994b). Our data showed a decrease in GS activity and
GSH levels in astrocytes from adult and aged rats compared to
newborn cultures. Thus, this methodology may represent an
important new tool for understanding the adult and aged brain.
Astrocytes are the major source of GSH. They synthesize and se-
crete GSH, which serves to neuronal GSH synthesis (Dringen, 2000;
Pope et al., 2008). The oxidation of GSH is observed in stress con-
ditions and aging, and it is inhibited by metal chelators and antiox-
idant enzymatic defense, such as superoxide dismutase and/or
exogen antioxidants (e.g. resveratrol) (Pope et al., 2008). In this
sense, resveratrol increased the GS activity and GSH levels in hip-
pocampal astrocytes. The increase in GSH confers neuroprotection
in neurodegenerative diseases, such as Alzheimer’s and Parkinson’s
diseases (Huang et al., 2011; Khan et al., 2010; Lee et al., 2010). In
addition, an increase in GS activity counteracts a possible toxicity
from high levels of glutamate. Therefore, these data reinforce the
antioxidant activity and neuroprotective effects of resveratrol.
Our group has shown that resveratrol modulates important glial
functions, such as glutamate uptake, GS activity, GSH content, anti-
oxidant enzymatic defenses and the inﬂammatory response under
different stress conditions (Bobermin et al., 2012; dos Santos et al.,
2006; Quincozes-Santos et al., 2010, 2007, 2013, 2009; Quincozes-
Santos and Gottfried, 2011). Recently, Quincozes-Santos et al.,
2013 reported that the heme oxygenase 1 (HO1) signaling pathway
is involved in the protective effects of resveratrol against H2O2-in-
duced oxidative damage in astroglial cells. Moreover, through HO1,
resveratrol can induce an endogenous cellular pathway that pro-
vides resistance against oxidative stress-related neural damage
and, consequently, a neuroprotective effect (Bastianetto and Quirion,
2010; Sakata et al., 2010). Furthermore, Nrf2, a transcription
factor that regulates HO1, also mediates neuroprotection and
modulates several detoxiﬁcation genes that encode antioxidant
proteins, such as the GSH system (Arredondo et al., 2010; Calabrese
et al., 2008; Calkins et al., 2009). Resveratrol may also activate Nrf2
(Calabrese et al., 2008; Erlank et al., 2011; Kode et al., 2008).
In addition, Lee et al., 2010 demonstrated that the depletion of
GSH stimulated the inﬂammatory response. Oxidative–nitrosative
stress plays a critical role in inﬂammatory response in astrocytes
(Tanabe et al., 2010). Here, we observed an increase in the levels
of the proinﬂammatory cytokines (TNF-a and IL-1b) in hippocam-
pal astrocytes from adult and aged rats compared to astrocytes
from newborn rats. TNF-a is essential for the production of other
cytokines involved in neuroinﬂammation, which is another process
associated with aging (Lee et al., 2010). TNF-a is synthesized
mainly by microglia and astrocytes and has several important
functions in the CNS, including astrocyte activation and glutama-
tergic gliotransmission (Santello et al., 2011; Santello and Volterra,
2012; Tanabe et al., 2010). Moreover, TNF-a and IL-1b are in-
creased in neurodegenerative disorders. We also demonstrated
that resveratrol decreased the levels of TNF-a and IL-1b in astro-
cytes from newborn, adult and aged rats, reinforcing the
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effects associated with neuroinﬂammation.
Even though its mechanisms of action are not fully understood,
resveratrol may exert its effects by antioxidant/scavenger activity
and/or by an anti-inﬂammatory effect. As the depletion of GSH
can induce neuroinﬂammation and neurotoxicity, both of which
are associated with aging, our data corroborated the anti-aging
effects demonstrated by resveratrol (Baur et al., 2006; Baur and
Sinclair, 2006; Kim et al., 2007). Moreover, astrocytes are a main
supplier of GSH to the CNS, and its depletion may cause neural
death. Thus, resveratrol emerges as an important neuroprotective
molecule. Studies in progress in our lab will evaluate the signaling
pathways involved in these effects of resveratrol in hippocampal
astrocyte cultures. Accordingly, the age-related glial responses of
resveratrol will also be studied.
In summary, for the ﬁrst time, we demonstrated a reduction of
antioxidant responses and an increase in proinﬂammatory
cytokines in hippocampal astrocyte cultures from adult and aged
Wistar rats compared to a classical newborn astrocyte culture. In
addition, the culture model described in this study elucidates the
biochemical and (patho)physiological properties of astrocytes
and may be useful for understanding the mechanisms involved in
aging and neurodegeneration. Furthermore, these observations
suggest that resveratrol may potentially be used as a neuroprotec-
tive anti-aging molecule, which is mainly associated with antioxi-
dant and anti-inﬂammatory effects.
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